Passage Bio and Remix Therapeutics Agree to Merge Into One Company
Passage Bio and Remix Therapeutics are joining forces in a merger deal. The combined company will carry the Remix name and focus on small molecule RNA therapies.
Two biotech companies are teaming up: Passage Bio and Remix Therapeutics have announced a merger agreement that will fold both firms into a single, unified operation. If you're not deep in the biotech weeds, think of it as one company absorbing another to pool resources, talent, and pipelines under a single roof.
Once the deal closes, the combined company will officially go by the name Remix Therapeutics — so Passage Bio's branding essentially fades into the background. That's a pretty clear signal about whose science is driving the bus here.
Read more West Michigan Data Center Lands Deal Worth Up to $1.2B →
The newly merged Remix will center its energy on advancing a pipeline of small molecule therapies, which are essentially tiny chemical compounds — as opposed to bulkier biologics like gene therapies — designed to tweak how cells process RNA. In plain English, RNA processing is a critical step in how your genes actually get turned into proteins, and when that process goes sideways, disease can follow. Remix's approach aims to fix problems at that fundamental level, targeting disease drivers at their root rather than just managing symptoms downstream.
This kind of RNA-reprogramming strategy is a relatively emerging area of drug development, and consolidating two companies' resources behind it could accelerate the science meaningfully. Mergers like this are increasingly common in biotech, especially when smaller firms want to extend their financial runway while doubling down on a focused therapeutic approach.
While specific financial terms of the deal were not disclosed in the announcement, the strategic rationale is clear: combine, rebrand, and push Remix's novel platform forward with a stronger foundation. Continue reading at GlobalNewswire.
